Moatazedi David's Insider Trades & SAST Disclosures
Moatazedi David's most recent trade in Evolus Inc was a trade of 103,376 Common Stock done at an average price of $13.3 . Disclosure was reported to the exchange on March 18, 2025.
Add Superstar Alert
Note
This is a custom search result for pattern Moatazedi David.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 13.26 per share. | 18 Mar 2025 | 103,376 | 514,870 (1%) | 0% | 13.3 | 1,370,249 | Common Stock |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 190,799 | 190,799 | - | - | Performance Restricted Stock Units | |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 135,925 | 135,925 | - | - | Stock Option (Right to Buy) | |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 95,399 | 618,246 (1%) | 0% | 0 | Common Stock | |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 10.85 per share. | 23 Dec 2024 | 10,502 | 522,847 (1%) | 0% | 10.9 | 113,967 | Common Stock |
|
Biomerica Inc.
|
David Moatazedi | Director | Grant, award, or other acquisition of securities at price $ 0.31 per share. | 13 Dec 2024 | 85,000 | 85,000 (0%) | 0% | 0.3 | 26,350 | Common stock |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.28 per share. | 04 Jun 2024 | 175,940 | 709,289 (2%) | 0% | 7.3 | 1,280,843 | Common Stock |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2024 | 175,940 | 1,006,079 | - | - | Stock Option (Right to Buy) | |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 12.59 per share. | 04 Jun 2024 | 175,940 | 533,349 (1%) | 0% | 12.6 | 2,214,486 | Common Stock |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.46 per share. | 04 Jun 2024 | 155,278 | 688,627 (2%) | 0% | 5.5 | 847,818 | Common Stock |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 12.92 per share. | 04 Jun 2024 | 155,278 | 533,349 (1%) | 0% | 12.9 | 2,006,456 | Common Stock |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2024 | 155,278 | 155,281 | - | - | Stock Option (Right to Buy) | |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 12.73 per share. | 04 Jun 2024 | 140,214 | 533,349 (1%) | 0% | 12.7 | 1,784,686 | Common Stock |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 12.72 per share. | 10 May 2024 | 16,051 | 673,563 (1%) | 0% | 12.7 | 204,127 | Common Stock |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 13.92 per share. | 19 Mar 2024 | 96,566 | 695,850 (2%) | 0% | 13.9 | 1,344,604 | Common Stock |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2024 | 61,202 | 800,122 (2%) | 0% | 0 | Common Stock | |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 13.08 per share. | 21 Feb 2024 | 7,706 | 792,416 (2%) | 0% | 13.1 | 100,804 | Common Stock |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 181,460 | 181,460 | - | - | Stock Option (Right to Buy) | |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 134,977 | 134,977 | - | - | Performance Restricted Stock Units | |
|
Evolus Inc
|
Moatazedi David | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 134,976 | 738,920 (2%) | 0% | 0 | Common Stock | |
|
Biomerica Inc.
|
David Moatazedi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2023 | 75,000 | 75,000 | - | - | Non-qualified stock option | |
|
Biomerica Inc.
|
David Moatazedi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2023 | 32,000 | 32,000 | - | - | Non-qualified stock option | |
|
Biomerica Inc.
|
David Moatazedi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2023 | 25,000 | 25,000 | - | - | Non-qualified stock option | |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 10.09 per share. | 06 Dec 2023 | 51,348 | 635,244 (1%) | 0% | 10.1 | 517,891 | Common Stock |
|
Evolus Inc
|
Moatazedi David | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 9.73 per share. | 06 Dec 2023 | 31,300 | 603,944 (1%) | 0% | 9.7 | 304,505 | Common Stock |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2023 | 91,803 | 701,370 (2%) | 0% | 0 | Common Stock | |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 10.27 per share. | 14 Aug 2023 | 14,778 | 686,592 (2%) | 0% | 10.3 | 151,770 | Common Stock |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2023 | 560,000 | 560,000 | - | - | Restricted Stock Units | |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 8.47 per share. | 27 Mar 2023 | 6,110 | 609,567 (1%) | 0% | 8.5 | 51,752 | Common Stock |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 8.47 per share. | 14 Mar 2023 | 64,211 | 615,677 (1%) | 0% | 8.5 | 543,797 | Common Stock |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 257,009 | 257,009 | - | - | Stock Option (Right to Buy) | |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 187,927 | 679,888 (2%) | 0% | 0 | Common Stock | |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 13.64 per share. | 16 May 2022 | 55,321 | 491,961 (1%) | 0% | 13.6 | 754,307 | Common Stock |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 11.62 per share. | 28 Mar 2022 | 6,104 | 547,282 (1%) | 0% | 11.6 | 70,928 | Common Stock |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 9.73 per share. | 08 Mar 2022 | 37,972 | 553,386 (1%) | 0% | 9.7 | 369,293 | Common Stock |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 310,559 | 310,559 | - | - | Stock Option (Right to Buy) | |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 214,286 | 591,358 (1%) | 0% | 0 | Common Stock | |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 11.35 per share. | 13 Aug 2021 | 47,737 | 377,072 (1%) | 0% | 11.3 | 541,739 | Common Stock |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 10.66 per share. | 13 Aug 2021 | 22,708 | 424,809 (1%) | 0% | 10.7 | 242,072 | Common Stock |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 11.18 per share. | 10 Aug 2021 | 41,763 | 447,517 (1%) | 0% | 11.2 | 466,839 | Common Stock |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2021 | 48,853 | 489,280 (1%) | 0% | 0 | Common Stock | |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jan 2021 | 266,667 | 440,427 (1%) | 0% | 0 | Common Stock | |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 7.46 per share. | 25 Jan 2021 | 8,310 | 173,760 (0%) | 0% | 7.5 | 61,993 | Common Stock |
|
Evolus Inc
|
David Moatazedi | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2020 | 100,000 | 182,070 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges